{"id":"NCT00911170","sponsor":"Amgen","briefTitle":"PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study","officialTitle":"A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Pegfilgrastim Admininstered to Subjects With Newly Diagnosed, Locally-advanced or Metastatic Colorectal Cancer Treated With Bevacizumab & Either 5-fluorouracil, Oxaliplatin, Leucovorin (FOLFOX) or 5-fluorouracil, Irinotecan, Leucovorin (FOLFIRI)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-11-03","primaryCompletion":"2012-09-17","completion":"2015-01-02","firstPosted":"2009-06-01","resultsPosted":"2014-01-07","lastUpdate":"2017-12-29"},"enrollment":847,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"SUPPORTIVE_CARE"},"conditions":["Cancer","Colon Cancer","Colorectal Cancer","Fever","Locally Advanced","Metastatic Colorectal Cancer","Neutropenia","Rectal Cancer"],"interventions":[{"type":"DRUG","name":"Pegfilgrastim","otherNames":["Neulasta®"]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"BIOLOGICAL","name":"Bevacizumab","otherNames":["Avastin®"]},{"type":"DRUG","name":"Standard Chemotherapy","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Pegfilgrastim","type":"PLACEBO_COMPARATOR"}],"summary":"This is a phase 3, randomized, double-blind, placebo-controlled multi-center study evaluating the efficacy of pegfilgrastim to reduce the incidence of febrile neutropenia (FN) in patients with newly diagnosed, locally-advanced or metastatic colorectal cancer receiving first-line treatment with bevacizumab and either 5-fluorouracil, Oxaliplatin, Leucovorin (FOLFOX) or 5-fluorouracil, Irinotecan, Leucovorin (FOLFIRI).\n\nThis study will also investigate the effect of adding pegfilgrastim to bevacizumab and either FOLFOX or FOLFIRI by evaluating overall survival, progression-free survival, and overall response rate in each arm at regular intervals over a maximum of 60 months follow-up.","primaryOutcome":{"measure":"Percentage of Participants With Grade 3/4 Febrile Neutropenia Across the First 4 Cycles of Chemotherapy","timeFrame":"Approximately 2 months duration (Daily for 4 cycles of treatment; 2 weeks per cycle)","effectByArm":[{"arm":"Placebo","deltaMin":5.7,"sd":null},{"arm":"Pegfilgrastim","deltaMin":2.4,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.014"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":15,"exclusionCount":18},"locations":{"siteCount":154,"countries":["United States","Australia","Belgium","Bulgaria","Canada","Czechia","France","Hungary","Ireland","Italy","Latvia","Mexico","Poland","Romania","Russia","Slovakia","Ukraine"]},"refs":{"pmids":["28038865"],"seeAlso":["http://www.amgentrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":56,"n":421},"commonTop":["Diarrhoea","Nausea","Neutropenia","Fatigue","Vomiting"]}}